These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29321380)

  • 1. Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.
    Lovshin JA; Boulet G; Lytvyn Y; Lovblom LE; Bjornstad P; Farooqi MA; Lai V; Cham L; Tse J; Orszag A; Scarr D; Weisman A; Keenan HA; Brent MH; Paul N; Bril V; Perkins BA; Cherney DZ
    JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease.
    Piani F; Reinicke T; Lytvyn Y; Melena I; Lovblom LE; Lai V; Tse J; Cham L; Orszag A; Perkins BA; Cherney DZI; Bjornstad P
    J Diabetes Complications; 2021 Mar; 35(3):107807. PubMed ID: 33288413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease.
    Ambinathan JPN; Sridhar VS; Lytvyn Y; Lovblom LE; Liu H; Bjornstad P; Perkins BA; Lovshin JA; Cherney DZI
    J Diabetes Complications; 2021 May; 35(5):107880. PubMed ID: 33678512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.
    Lytvyn Y; Bjornstad P; Lovshin JA; Boulet G; Farooqi MA; Lai V; Tse J; Cham L; Lovblom LE; Weisman A; Keenan HA; Brent MH; Paul N; Bril V; Advani A; Sochett E; Perkins BA; Cherney DZI
    Am J Kidney Dis; 2019 Jun; 73(6):786-796. PubMed ID: 30799029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
    Bjornstad P; Singh SK; Snell-Bergeon JK; Lovshin JA; Lytvyn Y; Lovblom LE; Rewers MJ; Boulet G; Lai V; Tse J; Cham L; Orszag A; Weisman A; Keenan HA; Brent MH; Paul N; Bril V; Perkins BA; Cherney DZI
    Diabetes Obes Metab; 2019 Mar; 21(3):575-583. PubMed ID: 30311395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes.
    Lytvyn Y; Har R; Locke A; Lai V; Fong D; Advani A; Perkins BA; Cherney DZI
    Diabetes; 2017 Jul; 66(7):1939-1949. PubMed ID: 28408434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
    Malek V; Suryavanshi SV; Sharma N; Kulkarni YA; Mulay SR; Gaikwad AB
    Rev Physiol Biochem Pharmacol; 2021; 179():31-71. PubMed ID: 32979084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes.
    Burns KD; Lytvyn Y; Mahmud FH; Daneman D; Deda L; Dunger DB; Deanfield J; Dalton RN; Elia Y; Har R; Van JA; Bradley TJ; Slorach C; Hui W; Xiao F; Zimpelmann J; Mertens L; Moineddin R; Reich HN; Sochett E; Scholey JW; Cherney DZ
    Am J Physiol Renal Physiol; 2017 Feb; 312(2):F335-F342. PubMed ID: 27733369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease.
    Klein J; Caubet C; Camus M; Makridakis M; Denis C; Gilet M; Feuillet G; Rascalou S; Neau E; Garrigues L; Thillaye du Boullay O; Mischak H; Monsarrat B; Burlet-Schiltz O; Vlahou A; Saulnier-Blache JS; Bascands JL; Schanstra JP
    Sci Rep; 2020 Sep; 10(1):14898. PubMed ID: 32913274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
    Price DA; De'Oliveira JM; Fisher ND; Williams GH; Hollenberg NK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):348-55. PubMed ID: 10232494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes.
    Lovshin JA; Lytvyn Y; Lovblom LE; Katz A; Boulet G; Bjornstad P; Lai V; Cham L; Tse J; Orszag A; Keenan HA; Paul N; Bril V; Wong DT; McReelis KD; Brent MH; Perkins BA; Cherney DZI
    Diabetes Care; 2019 Feb; 42(2):273-280. PubMed ID: 30523033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
    Pichler RH; de Boer IH
    Curr Diab Rep; 2010 Aug; 10(4):297-305. PubMed ID: 20532701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease.
    Wysocki J; Goodling A; Burgaya M; Whitlock K; Ruzinski J; Batlle D; Afkarian M
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F487-F494. PubMed ID: 28468961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.